• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.

作者信息

Kappel Ben A, Lehrke Michael, Schütt Katharina, Artati Anna, Adamski Jerzy, Lebherz Corinna, Marx Nikolaus

机构信息

From Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).

出版信息

Circulation. 2017 Sep 5;136(10):969-972. doi: 10.1161/CIRCULATIONAHA.117.029166.

DOI:10.1161/CIRCULATIONAHA.117.029166
PMID:28874423
Abstract
摘要

相似文献

1
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.恩格列净对2型糖尿病合并心血管疾病患者代谢特征的影响。
Circulation. 2017 Sep 5;136(10):969-972. doi: 10.1161/CIRCULATIONAHA.117.029166.
2
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.一项前瞻性随机研究：比较恩格列净与西格列汀对早期2型糖尿病患者心脏脂肪堆积、心脏功能和心脏代谢的影响——资产研究。
Cardiovasc Diabetol. 2021 Feb 2;20(1):32. doi: 10.1186/s12933-021-01228-3.
3
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.恩格列净治疗2型糖尿病合并外周动脉疾病患者的心血管结局及安全性：EMPA-REG OUTCOME研究的亚组分析
Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13.
4
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.恩格列净与 2 型糖尿病、已确诊心血管疾病和慢性肾脏病患者的临床结局。
Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
5
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.恩格列净改善心血管结局独立于血糖控制。
Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759.
6
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?心力衰竭中利尿剂抵抗：恩格列净有作用吗？
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
7
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.恩格列净降低2型糖尿病合并心血管疾病患者的心血管死亡率
J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022.
8
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.恩格列净可降低 2 型糖尿病患者的血压和尿酸：系统评价和荟萃分析。
J Hum Hypertens. 2019 Apr;33(4):327-339. doi: 10.1038/s41371-018-0134-2. Epub 2018 Nov 15.
9
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME.在 EMPA-REG OUTCOME 研究中观察到的心血管结局与 LDL-胆固醇水平。
Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120975256. doi: 10.1177/1479164120975256.
10
Introduction.引言。
Am J Med. 2017 Jun;130(6S):S1-S3. doi: 10.1016/j.amjmed.2017.04.003.

引用本文的文献

1
Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes.代谢组学揭示钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病的益处
Clin Pharmacol. 2025 Aug 31;17:253-267. doi: 10.2147/CPAA.S497906. eCollection 2025.
2
Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors.探索脱节之处：钠-葡萄糖协同转运蛋白2抑制剂未能改善身体功能的潜在机制。
Front Syst Biol. 2025 May 30;5:1593229. doi: 10.3389/fsysb.2025.1593229. eCollection 2025.
3
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure.
钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂对心力衰竭生物标志物的影响
Cells. 2025 Jun 18;14(12):919. doi: 10.3390/cells14120919.
4
Regenerative therapies for myocardial infarction: exploring the critical role of energy metabolism in achieving cardiac repair.心肌梗死的再生疗法：探索能量代谢在实现心脏修复中的关键作用。
Front Cardiovasc Med. 2025 Feb 7;12:1533105. doi: 10.3389/fcvm.2025.1533105. eCollection 2025.
5
Myocardial metabolic flexibility following ketone infusion demonstrated by hyperpolarized [2-C]pyruvate MRS in pigs.猪体内通过超极化[2-C]丙酮酸磁共振波谱法证明的酮输注后心肌代谢灵活性。
Sci Rep. 2025 Feb 18;15(1):5849. doi: 10.1038/s41598-025-90215-9.
6
Cardiovascular outcomes of SGLT-2 inhibitors' subtypes in type 2 diabetes; an updated systematic review and meta-analysis of randomized controlled trials.2型糖尿病中SGLT-2抑制剂各亚型的心血管结局；随机对照试验的最新系统评价和荟萃分析
J Diabetes Metab Disord. 2025 Jan 13;24(1):47. doi: 10.1007/s40200-024-01545-w. eCollection 2025 Jun.
7
Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes.在CREDENCE试验中，2型糖尿病患者的空腹底物可预测慢性肾脏病进展。
JCI Insight. 2024 Dec 20;9(24):e180637. doi: 10.1172/jci.insight.180637.
8
Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.达格列净对2型糖尿病患者血清代谢组的影响。
J Diabetes Metab Disord. 2024 Dec 16;24(1):4. doi: 10.1007/s40200-024-01508-1. eCollection 2025 Jun.
9
Multifaceted Impact of SGLT2 Inhibitors in Heart Failure Patients: Exploring Diverse Mechanisms of Action.钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭患者的多方面影响：探索多种作用机制
Biomedicines. 2024 Oct 11;12(10):2314. doi: 10.3390/biomedicines12102314.
10
Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitors.基于精细映射的多组学分析阐释 SGLT2 抑制剂的肠-肺轴功能。
Front Cell Infect Microbiol. 2024 Sep 10;14:1447327. doi: 10.3389/fcimb.2024.1447327. eCollection 2024.